High Note Wealth’s Biogen BIIB Stock Holding History

High Note Wealth’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.8K	Buy	110 +5	+5%	+$956	﹤0.01%	272
2026 Q1	$19.3K	Buy	105 +9	+9%	+$1.66K	﹤0.01%	279
2025 Q4	$16.9K	Sell	96 -3	-3%	-$490	﹤0.01%	281
2025 Q3	$13.9K	Buy	99 +64	+183%	+$8.65K	﹤0.01%	284
2025 Q2	$4.4K	Hold	35	–	–	﹤0.01%	480
2025 Q1	$4.79K	Sell	35 -22	-39%	-$3.15K	﹤0.01%	429
2024 Q4	$8.68K	Buy	+57	New	+$9.61K	﹤0.01%	312
2021 Q4	–	Sell	-6,766	Closed	-$1.91M	–	85
2021 Q3	$1.91M	Buy	6,766 +11	+0.2%	+$3.6K	0.69%	42
2021 Q2	$2.34M	Sell	6,755 -69	-1%	-$20.9K	0.85%	41
2021 Q1	$1.91M	Buy	6,824 +235	+4%	+$63.4K	0.74%	44
2020 Q4	$1.61M	Buy	+6,589	New	+$1.7M	0.69%	45

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

High Note Wealth's BIIB Position: Q2 2026 in Review

High Note Wealth increased its Biogen (BIIB) stake by 4.8% in Q2 2026, buying an estimated $956 and bringing the position to 110 shares worth $23.8K. The position accounts for ﹤0.01% of the portfolio, ranked #272.

High Note Wealth first reported a position in BIIB in Q4 2020 and has held it in 11 quarters since. The position peaked at $2.34M in Q2 2021. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

High Note Wealth held 110 shares of Biogen worth $23.8K as of Q2 2026.
High Note Wealth bought 5 Biogen shares in Q2 2026, an estimated $956.
Biogen made up ﹤0.01% of High Note Wealth's portfolio in Q2 2026, its #272 holding.
High Note Wealth first reported a position in Biogen in Q4 2020 and has held it in 11 quarters since.
High Note Wealth's Biogen position peaked at $2.34M in Q2 2021.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on High Note Wealth's 13F filing for Q2 2026, filed 23 Jul 2026.